Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilvadipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 0.60 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 0.60 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 0.60 |
| ▸ | CACNA1C known ✓ | Q13936 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilvadipine SCHEMBL11913265 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL30875962 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL8004036 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL33730 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL33729 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| SCHEMBL7380227 | 0.94 | ADORA3 (0.89) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL8170123 | 0.94 | ADORA3 (0.88) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL1538947 | 0.93 | ADORA3 (0.87) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL7625807 | 0.93 | ADORA3 (0.85) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| SCHEMBL30357961 | 0.90 | ADORA3 (0.81) | ADORA3NR1I2NR3C1ABCB1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2006-06-22 | — | — | US | disclosed |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-07-21 | — | — | US | disclosed |
| WO-2005018755-A2 | MULTILAYER GOLF BALL | TAYLORMADE-ADIDAS GOLF COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2002085468-A1 | GOLF BALL WITH DUAL CORE AND POLYURETHANE COVER | SPALDING SPORTS WORLDWIDE, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002056975-A1 | GOLF BALL | SPALDING SPORTS WORLDWIDE, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002002194-A1 | MULTI-LAYER GOLF BALL WITH REACTION INJECTION MOLDED POLYURETHANE COMPONENT | SPALDING SPORTS WORLDWIDE, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001068193-A2 | MULTILAYER GOLF BALL WITH FILLED INNER LAYER HAVING DUAL CORE, LIQUID CORE, OR WOUND CORE | SPALDING SPORTS WORLDWIDE, INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068192-A1 | DISTANCE MULTI-LAYER GOLF BALL | SPALDING SPORTS WORLDWIDE, INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001052945-A1 | IMPROVED MULTI-LAYER GOLF BALL | SPALDING SPORTS WORLDWIDE, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001052943-A1 | IMPROVED MULTI-LAYER GOLF BALL | SPALDING SPORTS WORLDWIDE, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| US-6159110-A | Golf ball utilizing silicone materials | SPALDING SPORTS WORLDWIDE, INC. | 2000-12-12 | — | — | US | disclosed |
| US-6150470-A | NEUTRALIZED ETHYLENE-(METH)ACRYLIC ACID POLYMER | SPALDING SPORTS WORLDWIDE, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6120393-A | A COVER COMPRISING A HIGH ACID IONOMER RESIN INCLUDING A COPOLYMER OF >16% BY WEIGHT OF AN ALPHA, BETA-UNSATURATED CARBOXYLIC ACID AND AN ALPHA OLEFIN, OF WHICH ABOUT 10-90% OF THE CARBOXYL GROUPS OF THE COPOLYMER ARE NEUTRALIZED | SPALDING SPORTS WORLDWIDE, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-6015356-A | Golf ball and method of producing same | LISCO, INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-5971872-A | Low spin golf ball | LISCO, INC. | 1999-10-26 | — | — | US | disclosed |
| US-5820489-A | A SOFT DIENE POLYMER CORE AND A HIGH ACID IONOMER HARD COVER; REDUCING THE CORE WEIGHT WHILE INCREASING THE THICKNESS OF COVER FOR REDUCING THE BALL SPINNING | LISCO, INC. (US) | 1998-10-13 | — | — | US | disclosed |
| US-5803831-A | MULTILAYER | LISCO INC. (US) | 1998-09-08 | — | — | US | disclosed |
| US-5733207-A | DIENE POLYMER CORE, IONOMER COVERING | LISCO, INC. (US) | 1998-03-31 | — | — | US | disclosed |
| US-5368304-A | Diene polymer coreswith ionomer coverings | LISCO, INC. (US) | 1994-11-29 | — | — | US | disclosed |
| US-5312857-A | Ionomer resin of olefin and unsaturated monocarboxylic acid and metal stearate | LISCO, INC. (US) | 1994-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PTGS2, PTGES2, PTGS1 | CACNA1F 127/4885CACNA1D 140/4885CACNA1S 145/4885 |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PTGS2, PTGS1, PTGIS | CACNA1F 67/4885CACNA1D 60/4885CACNA1S 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.